IL13 and neoplasm: As both SIM and DOX induced significant angiogenic effects in vivo by nano-formulation-mediated delivery (Licarete et al., 2020; Rauca et al., 2021), we evaluated intratumor angiogenic and inflammatory protein production in whole tumor lysates after administration of 5 mg/kg IL-13-LCL-SIM and 2 mg/kg PEG-EV-DOX as monotherapies and sequential therapy.